Intracavernous Sodium Nitroprusside: Inappropriate Impotence Treatment
Authors:
- 1 September 1993
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (3) , 864-867
Abstract
On the basis of reports describing nitric oxide as a form of endothelium-derived relaxing factor and on our own experience with intracavernous use of nitric oxide-releasing substances in animal models, we undertook an approved human study of intracavernous sodium nitroprusside as a treatment for impotence. We report our early experience in which severe hypotension and only mild tumescence in our first 3 patients caused us to discontinue the trial.Keywords
This publication has 18 references indexed in Scilit:
- Nitric Oxide: First in a New Class of NeurotransmittersScience, 1992
- Nitric Oxide: A Physiologic Mediator of Penile ErectionScience, 1992
- Biosynthesis of nitric oxide and citrulline from l-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosumBiochemical and Biophysical Research Communications, 1992
- Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic NeurotransmissionNew England Journal of Medicine, 1992
- Nitric oxide, a novel neuronal messengerNeuron, 1992
- A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle.Journal of Clinical Investigation, 1991
- Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscleBiochemical and Biophysical Research Communications, 1990
- The discovery of nitric oxide as the endogenous nitrovasodilator.Hypertension, 1988
- INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILUREThe Lancet, 1982
- Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferensNature, 1977